X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AR1001 is a phosphodiesterase-5 (PDE5) inhibitor being developed as an investigational oral agent being investigated for the treatment of early Alzheimer’s disease.
Lead Product(s): Methylbenzylamine
Therapeutic Area: Neurology Product Name: AR1001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2024
Details:
AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.
Lead Product(s): Methylbenzylamine
Therapeutic Area: Neurology Product Name: AR1001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity, also has demonstrated notable effects against amyloid plaques and tau proteins via autophagy activation.
Lead Product(s): Methylbenzylamine
Therapeutic Area: Neurology Product Name: AR1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
Positive Phase II trial reported for AR1001, the results confirmed the possibility of developing a unique oral disease-modifying treatment for AD that improves cognitive function. The Company will complete Phase III clinical trials of AR1001 within the next 3-4 years.
Lead Product(s): Methylbenzylamine
Therapeutic Area: Neurology Product Name: AR1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cleveland Clinic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021
Details:
AriBio completed enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease.
Lead Product(s): Methylbenzylamine
Therapeutic Area: Neurology Product Name: AR1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SK Chemicals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
